At a glance
- Originator Pfizer
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 15 Feb 1995 Discontinued-Preclinical for Hyperlipidaemia in USA (Unknown route)